# US 2025/0085279 A1 · Assay to determine in vivo receptor occupancy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0085279 A1
- Document ID: US20250085279A1
- Status: Published application
- Kind: A1
- Application number: 18/791,084
- Filed: 2024-07-31
- Published: 2025-03-13
- Earliest claimed: 2018-05-10
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Naiyu ZHENG; Ian MacQuarie CATLETT; Jianing ZENG
- Web page: https://patentgrep.com/patent/US20250085279A1

## CPC

- G01N 33/54393: {Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding}
- G01N 33/6851: {Methods of protein analysis involving laser desorption ionisation mass spectrometry}
- G01N 2030/027: {Liquid chromatography}
- G01N 2333/912: transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to assays for monitoring and measuring the binding of a drug of interest to a receptor. In this assay, a blood sample collected from a subject dosed with the compound of interest is incubated with a lysis solution containing a quencher. The drug bound and quencher bound receptor is then isolated from the lysed blood sample. The isolated drug bound and quencher bound receptor is digested to generate surrogate drug bound and quencher bound peptides. The amount of surrogate peptides is determined. Receptor occupancy can be determined by comparing the amount of drug bound surrogate peptide to the total of drug bound and quencher bound surrogate peptide.

## Claims

### Claim 1

An assay method for determining receptor occupancy comprising:
a) contacting a blood sample collected from a subject with a lysis solution comprising a quencher, wherein the subject was administered a compound of interest that irreversibly binds a receptor,
b) isolating the receptor,
c) digesting the isolated receptor to generate surrogate peptides, and
d) measuring the amount of the surrogate peptides and determining drug receptor occupancy by comparing the amount of compound bound surrogate peptides to the total amount of compound bound and quencher bound surrogate peptides.

### Claim 2

An assay method for determining drug receptor occupancy in a subject dosed with a drug of interest that covalently binds to a receptor of interest comprising:
a) contacting a blood sample obtained from the subject with a lysis solution, wherein the subject was treated with a drug of interest, and wherein the lysis solution comprises comprising a quencher that irreversibly binds at the same receptor site as the drug of interest to the blood sample,
b) isolating drug bound and quencher bound receptor by immunocapture,
c) digesting the isolated drug bound and quencher bound receptor to generate drug bound and quencher bound surrogate peptides, and
d) measuring the amount of surrogate peptides using LC-MS/MS and determining the amount of receptor bound to drug by comparing the amount of drug bound surrogate peptides to the total amount of drug bound and quencher bound surrogate peptides.

### Claim 3 (depends on 2)

The assay of claim 2, wherein the drug of interest is shown in FIG. 1A.

### Claim 4 (depends on 2)

The assay of claim 2, wherein the quencher of step (b) is shown in FIG. 1B.

### Claim 5 (depends on 1)

The assay of claim 1, wherein digestion step (d) is trypsin digestion.

### Claim 6 (depends on 1)

The assay of claim 1, wherein the amount of surrogate peptides is measured by LC-MS/MS.

### Claim 7

A method for determining BTK receptor occupancy in a subject dosed with a drug, wherein the drug is shown in FIG. 1A comprising:
a) adding contacting a blood sample obtained from the subject with a lysis solution containing the comprising a quencher, wherein the quencher is shown in FIG. 1B,
b) isolating drug bound and quencher bound BTK with anti-BTK biotinylated antibody bound to Streptavidin T1 Beads,
c) digesting the isolated drug bound and quencher bound BTK-antibody complex with trypsin to generate surrogate peptides, and
d) measuring the amount of surrogate peptides using LC-MS/MS chromatography and determining the amount of BTK bound to drug by comparing the amount of drug bound surrogate peptide to the total amount of drug bound and quencher bound surrogate peptides.
